|Articles|May 12, 2008

Cardinal Health Completes Enturia Acquisition

DUBLIN, Ohio -- Cardinal Health, a global provider of products and services that improve the safety and productivity of healthcare, today announced it has completed the acquisition of assets of privately held Enturia, Inc., the manufacturer of infection prevention products sold under the ChloraPrep(R) brand name.

ChloraPrep(R) brand products are used widely in U.S. hospitals and surgery centers as a patient preoperative skin preparation to help prevent bloodstream and surgical site infections, two of the most common types of healthcare-associated infections (HAIs) among surgery patients. The products use proprietary disposable applicators to deliver a clinically preferred concentration of chlorhexidine gluconate (CHG) that penetrates the first five cell layers of the skin to help reduce skin-dwelling microorganisms that cause infections. The applicator design eliminates direct hand-to-patient contact, helping prevent cross-contamination.

The ChloraPrep(R) product line expands the company's offerings that help providers lower infection rates. Cardinal Health's infection prevention portfolio ranges from MedMined(TM) electronic infection surveillance services to medical products and surgical apparel. Cardinal Health plans to accelerate sales of ChloraPrep(R) products to both hospital and alternate-care customers through its U.S. and international sales networks.

Source: Cardinal Health


Related to this article

Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.